Profusa

Profusa

Profusa was founded in 2008 by Ben Hwang and Natalie Wisniewski, emerging from early work in bioengineered polymers that could integrate with living tissue without triggering the body's foreign-body response. The company operates out of South San Francisco, positioning itself at the intersection of medical devices and digital health rather than as a lifestyle wearables firm. Its foundational insight was that chronic disease monitoring required sensors that work inside the body continuously, not from a wrist-based optical reading. The company's Lumee platform relies on tissue-integrated hydrogel microsensors, each a fraction of an inch long, placed subcutaneously. A wearable optical reader on the skin surface detects fluorescent signals from the sensors, translating them into oxygen, glucose, or lactate concentration data. In 2020, Profusa received CE Mark approval for the Lumee Oxygen Platform for chronic wound monitoring, and the DARPA-backed program tested the sensors in harsh combat-environment conditions to monitor soldier physiology. The platform targets chronic conditions including peripheral artery disease, diabetes, and tissue ischemia, with deployment spanning the U.S. military's medical research commands and European clinical sites. Profusa has raised over $140 million in total disclosed funding from a syndicate of venture and strategic investors (per the company's disclosed financings). Backers include VMS Group, the primary investment vehicle for the family of the late British billionaire property investor Vincent Tchenguiz, alongside traditional venture capital firms. The company's workforce is estimated at roughly 50–100 professionals, weighted toward bioengineering, clinical regulation, and data science. In September 2022, Profusa opened a clinical study in partnership with the U.S. Army to evaluate continuous lactate monitoring in divers, illustrating the dual-use nature of the sensor platform across civilian and defense applications. What structurally differentiates Profusa from continuous glucose monitor incumbents like Abbott and Dexcom is the hydrogel integration layer. Conventional continuous monitors rely on an electrochemical needle that eventually degrades and must be replaced every 7–14 days. Profusa's hydrogel is designed to remain stable for months or years, turning the body's interstitial fluid into a persistent data source rather than a weekly consumable. The trade-off is a longer regulatory path: Profusa functions more like a Class III implantable medical device than a consumer electronic, which shapes the firm's slower, clinical-first commercial cadence.